viernes, 2 de diciembre de 2016
FDA Approves Nivolumab for Head and Neck Cancer
The Food and Drug Administration (FDA) approved nivolumab (Opdivo®) on November 10 for the treatment of squamous cell cancer of the head and neck (SCCHN). Nivolumab is already approved for the treatment of several other cancers. This new approval is for the use of nivolumab in patients with SCCHN that has progressed during chemotherapy with a platinum-based drug or that has recurred or metastasized after platinum-based chemotherapy.